5 Matching Annotations
  1. Last 7 days
  2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    Untitled document
    5
    1. karim2001khoury 19 Feb 2026
      Emerging a Novel VOPP1-EGFR Fusion Coexistent With T790M as an Acquired Resistance Mechanism to Prior Icotinib and Sensitive to Osimertinib in a Patient With EGFR L858R Lung Adenocarcinoma: A Case Report

      [Paper-level Aggregated] PMCID: PMC8727519

      Evidence Type(s): Oncogenic, Predictive, Prognostic

      Justification: Oncogenic: The presence of the EGFR L858R and T790M variants in the patient's lung adenocarcinoma indicates their role in tumorigenesis and resistance to treatment, supporting their classification as oncogenic. Predictive: The identification of the T790M variant suggests a potential resistance mechanism to first-generation EGFR tyrosine kinase inhibitors, indicating its predictive value for treatment response. Prognostic: The patient's progression-free survival interval of more than 11 months after switching to osimertinib suggests that the presence of the T790M variant may have prognostic implications for treatment outcomes in NSCLC.

      Gene→Variant (gene-first): EGFR(1956):L858R EGFR(1956):T790M

      Genes: EGFR(1956)

      Variants: L858R T790M

      CIViC paper-level aggregated PMC8727519
    2. karim2001khoury 19 Feb 2026
      The present results suggested that acquired VOPP1-EGFR fusion gene with T790M potentially serve an additional resistance mechanism to first-generation EGFR tyrosine kinase inhibitors in EGFR-mutated NSCLC. And the presen

      [Paragraph-level] PMCID: PMC8727519 Section: ABSTRACT PassageIndex: 6

      Evidence Type(s): Predictive, Oncogenic

      Justification: Predictive: The passage discusses T790M as a resistance mechanism to first-generation EGFR tyrosine kinase inhibitors, indicating its correlation with treatment response. Oncogenic: The mention of T790M in the context of an acquired resistance mechanism suggests that it contributes to tumor progression in EGFR-mutated NSCLC.

      Gene→Variant (gene-first): 1956:T790M

      Genes: 1956

      Variants: T790M

      CIViC paragraph-level PMC8727519 Predictive Oncogenic
    3. karim2001khoury 19 Feb 2026
      In this case report, we describe a 69-year-old female who received right lobectomy and was diagnosed with pathological stage IIIA lung adenocarcinoma harboring EGFR L858R. Twenty months later he had recurrent disease in

      [Paragraph-level] PMCID: PMC8727519 Section: ABSTRACT PassageIndex: 4

      Evidence Type(s): Predictive, Oncogenic

      Justification: Predictive: The passage discusses the T790M variant as a potential resistance mechanism to icotinib treatment, indicating its correlation with treatment response. Oncogenic: The L858R variant is described as being present in a patient with lung adenocarcinoma, suggesting its role in tumor development or progression.

      Gene→Variant (gene-first): 1956:L858R 1956:T790M

      Genes: 1956

      Variants: L858R T790M

      CIViC paragraph-level PMC8727519 Predictive Oncogenic
    4. karim2001khoury 19 Feb 2026
      The present results suggested that acquired VOPP1-EGFR fusion gene with T790M potentially serve an additional resistance mechanism to first-generation EGFR tyrosine kinase inhibitors in EGFR-mutated NSCLC. And the presen

      [Paragraph-level] PMCID: PMC8727519 Section: ABSTRACT PassageIndex: 6

      Evidence Type(s): Predictive, Oncogenic

      Justification: Predictive: The passage discusses T790M as a resistance mechanism to first-generation EGFR tyrosine kinase inhibitors, indicating its correlation with treatment response. Oncogenic: The mention of T790M in the context of an acquired resistance mechanism suggests that it contributes to tumor progression in EGFR-mutated NSCLC.

      Gene→Variant (gene-first): 1956:T790M

      Genes: 1956

      Variants: T790M

      CIViC paragraph-level PMC8727519 Predictive Oncogenic
    5. karim2001khoury 19 Feb 2026
      In this case report, we describe a 69-year-old female who received right lobectomy and was diagnosed with pathological stage IIIA lung adenocarcinoma harboring EGFR L858R. Twenty months later he had recurrent disease in

      [Paragraph-level] PMCID: PMC8727519 Section: ABSTRACT PassageIndex: 4

      Evidence Type(s): Predictive, Oncogenic

      Justification: Predictive: The passage discusses the T790M variant as a potential resistance mechanism to icotinib treatment, indicating its correlation with treatment response. Oncogenic: The L858R variant is described as being present in a patient with lung adenocarcinoma, suggesting its role in tumor development or progression.

      Gene→Variant (gene-first): 1956:L858R 1956:T790M

      Genes: 1956

      Variants: L858R T790M

      CIViC paragraph-level PMC8727519 Predictive Oncogenic
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC8727519/pdf/fonc-11-720819.pdf